Alecnib (Alectinib) Capsules
19787โด
21106โด
-6%
Alecnib 150 mg (Alectinib) is a highly selective second-generation ALK (anaplastic lymphoma kinase) inhibitor.
Manufacturer: Everest Pharmaceuticals. Each pack contains 56 capsules. It targets and blocks the ALK protein in cancer cells. It is particularly noted for its systemic activity and efficacy against brain metastases.
Key Feature:
Standard of care for ALK-positive lung cancer due to its ability to cross the blood-brain barrier and prolonged progression-free survival.
Indicated for the treatment of adult patients with:
- ๐น ALK-positive NSCLC: Advanced or metastatic Non-Small Cell Lung Cancer that is ALK-positive (detected by an FDA-approved test).
- ๐น Usage: First-line treatment or for patients who have progressed on crizotinib.
Packaging: 150 mg capsules.
โ ๏ธ ADMINISTRATION PROTOCOL:
- Recommended Dose: 600 mg orally twice daily.
- Pill Count: Take 4 capsules (150 mg each) twice a day (morning and evening).
- Food Intake: Must be taken with food to ensure proper absorption.
- Administration: Swallow capsules whole. Do not open or dissolve.
- Supply Note: One pack of 56 capsules lasts for 7 days at the standard dosage.
- Hypersensitivity to Alectinib.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
- Severe hepatic impairment (precaution required).
Common adverse reactions include:
- ๐ฉธ Cardiovascular/Muscular: Bradycardia (slow heart rate), myalgia (muscle pain), increased CPK levels.
- ๐ Gastrointestinal: Constipation (very common), nausea, hyperbilirubinemia.
- ๐ Physical: Edema (swelling of hands, feet, or eyes), photosensitivity (sunburn propensity).
- โ ๏ธ Warning: Patients should use sunscreen and avoid prolonged sun exposure during treatment.
100% original product
Delivery across Ukraine
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!